.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
This trial randomized 245 early-stage HR+ breast cancer patients to receive adjuvant endocrine therapy (ET) in the morning or evening. The primary endpoint, change in FACT-ES score at 12 weeks, showed no significant difference between groups. No statistical differences were observed in any secondary endpoints, including toxicity, tolerability, quality of life, non-persistence, non-adherence, or patient preference.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
This trial randomized 245 early-stage HR+ breast cancer patients to receive adjuvant endocrine therapy (ET) in the morning or evening. The primary endpoint, change in FACT-ES score at 12 weeks, showed no significant difference between groups. No statistical differences were observed in any secondary endpoints, including toxicity, tolerability, quality of life, non-persistence, non-adherence, or patient preference.
2 months ago
Discover the crucial role of glymphatic dysfunction in stroke, where perivascular clearance failure and neuroinflammation exacerbate cerebral edema and post-stroke brain injury.
Today
A prenatal case highlights severe glutaric acidemia type II presenting as bilateral hyperechoic cystic kidneys at 18 weeks. Whole-exome sequencing revealed a novel homozygous ETFDH frameshift variant, demonstrating the power of rapid genetic testing in fetal renal anomalies.
Today
Review how tailored exercise programs benefit frail older patients with heart failure. Explore pathophysiological mechanisms, individualized training prescriptions, and strategies to overcome adherence barriers in clinical practice.
Yesterday
This comparative study evaluates posterior labral tears with and without glenohumeral instability, highlighting distinct demographic patterns, MRI underestimation in stable shoulders, and successful arthroscopic repair outcomes.
Yesterday
A clinical study demonstrates that early intervention with tocilizumab, either as monotherapy or bridged with corticosteroids, achieves significant proptosis reduction and resolves active inflammation in treatment-naive thyroid eye disease.
Yesterday
